 David Higgins
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 3 | 2023 | 66 | 2.250 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2023 | 428 | 1.140 |
Why?
| | Hepatitis B Vaccines | 1 | 2023 | 43 | 0.770 |
Why?
| | Rural Health Services | 1 | 2024 | 141 | 0.770 |
Why?
| | Gonorrhea | 1 | 2023 | 65 | 0.730 |
Why?
| | Sexual Health | 1 | 2023 | 66 | 0.730 |
Why?
| | Chlamydia Infections | 1 | 2023 | 81 | 0.730 |
Why?
| | Physicians, Primary Care | 1 | 2024 | 207 | 0.710 |
Why?
| | Sexually Transmitted Diseases | 1 | 2023 | 166 | 0.670 |
Why?
| | Ventricular Function, Left | 4 | 2025 | 541 | 0.650 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 246 | 0.650 |
Why?
| | Mitral Valve Insufficiency | 3 | 2024 | 72 | 0.590 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 251 | 0.580 |
Why?
| | Vaccines | 1 | 2023 | 389 | 0.560 |
Why?
| | Vaccination | 5 | 2024 | 1423 | 0.550 |
Why?
| | HIV Infections | 2 | 2023 | 3154 | 0.540 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2017 | 62 | 0.500 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1185 | 0.480 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 888 | 0.470 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1356 | 0.450 |
Why?
| | Mycobacterium tuberculosis | 5 | 2010 | 334 | 0.440 |
Why?
| | Magnetic Resonance Imaging, Cine | 3 | 2025 | 214 | 0.430 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2017 | 359 | 0.420 |
Why?
| | Telemedicine | 1 | 2023 | 945 | 0.410 |
Why?
| | Tuberculosis, Pulmonary | 3 | 2010 | 131 | 0.410 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2023 | 17 | 0.400 |
Why?
| | Heart Ventricles | 1 | 2017 | 760 | 0.370 |
Why?
| | Interleukin-10 | 3 | 2014 | 309 | 0.350 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 186 | 0.310 |
Why?
| | Stroke Volume | 3 | 2024 | 651 | 0.310 |
Why?
| | Cross Infection | 1 | 2012 | 262 | 0.300 |
Why?
| | Implants, Experimental | 1 | 2009 | 21 | 0.300 |
Why?
| | Mitral Valve | 3 | 2024 | 96 | 0.300 |
Why?
| | Foreign-Body Reaction | 1 | 2009 | 36 | 0.290 |
Why?
| | Vitamin D | 1 | 2012 | 400 | 0.280 |
Why?
| | Tuberculosis | 3 | 2010 | 291 | 0.280 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2008 | 19 | 0.280 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 161 | 0.250 |
Why?
| | Length of Stay | 1 | 2012 | 1337 | 0.240 |
Why?
| | Pregnancy | 3 | 2023 | 7190 | 0.240 |
Why?
| | Female | 17 | 2025 | 78271 | 0.240 |
Why?
| | Edema, Cardiac | 1 | 2025 | 2 | 0.230 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2025 | 3 | 0.230 |
Why?
| | Intensive Care Units | 1 | 2012 | 916 | 0.230 |
Why?
| | Critical Illness | 1 | 2012 | 891 | 0.230 |
Why?
| | Humans | 21 | 2025 | 144759 | 0.230 |
Why?
| | Biocompatible Materials | 1 | 2009 | 435 | 0.220 |
Why?
| | Pandemics | 2 | 2023 | 1694 | 0.220 |
Why?
| | Ventricular Function, Right | 2 | 2024 | 297 | 0.220 |
Why?
| | Mass Screening | 2 | 2023 | 1347 | 0.210 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2115 | 0.210 |
Why?
| | Heart Failure | 1 | 2017 | 2323 | 0.200 |
Why?
| | Blood Coagulation Tests | 1 | 2023 | 70 | 0.200 |
Why?
| | Hepatitis B virus | 1 | 2023 | 33 | 0.190 |
Why?
| | Sepsis | 2 | 2022 | 640 | 0.180 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 49 | 0.180 |
Why?
| | HIV | 1 | 2023 | 250 | 0.180 |
Why?
| | Ventricular Remodeling | 1 | 2024 | 276 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2023 | 222 | 0.170 |
Why?
| | Infant, Newborn | 2 | 2023 | 6429 | 0.170 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2023 | 193 | 0.170 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 157 | 0.170 |
Why?
| | Exercise Test | 1 | 2024 | 634 | 0.170 |
Why?
| | Child | 6 | 2024 | 22633 | 0.160 |
Why?
| | Myocardium | 1 | 2025 | 939 | 0.160 |
Why?
| | Macrophages | 1 | 2008 | 1511 | 0.160 |
Why?
| | Disease Progression | 3 | 2017 | 2847 | 0.160 |
Why?
| | Pneumonia, Aspiration | 2 | 2013 | 16 | 0.150 |
Why?
| | Retrospective Studies | 4 | 2023 | 17066 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1095 | 0.150 |
Why?
| | Influenza Vaccines | 1 | 2024 | 529 | 0.150 |
Why?
| | Infant | 2 | 2024 | 10034 | 0.150 |
Why?
| | Echocardiography | 2 | 2024 | 652 | 0.150 |
Why?
| | Chemokines, C | 2 | 2008 | 5 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 730 | 0.140 |
Why?
| | Genomics | 1 | 2023 | 834 | 0.140 |
Why?
| | Deglutition Disorders | 2 | 2013 | 147 | 0.130 |
Why?
| | Male | 11 | 2025 | 72315 | 0.130 |
Why?
| | Ferritins | 1 | 2017 | 69 | 0.130 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 635 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2023 | 767 | 0.130 |
Why?
| | Adult | 7 | 2025 | 40449 | 0.130 |
Why?
| | United States | 2 | 2024 | 15966 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3863 | 0.120 |
Why?
| | Transforming Growth Factor beta | 2 | 2009 | 479 | 0.120 |
Why?
| | Lung | 5 | 2013 | 4109 | 0.110 |
Why?
| | Tracheostomy | 1 | 1997 | 142 | 0.110 |
Why?
| | Iron | 1 | 2017 | 359 | 0.110 |
Why?
| | Parents | 1 | 2023 | 1403 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1414 | 0.110 |
Why?
| | Cytokines | 4 | 2010 | 2061 | 0.110 |
Why?
| | Th1 Cells | 3 | 2010 | 139 | 0.100 |
Why?
| | Colorado | 1 | 2024 | 4564 | 0.100 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2013 | 21 | 0.100 |
Why?
| | Primary Health Care | 1 | 2024 | 1733 | 0.100 |
Why?
| | Propranolol | 1 | 2013 | 44 | 0.100 |
Why?
| | Mice | 9 | 2014 | 18339 | 0.100 |
Why?
| | Middle Aged | 5 | 2025 | 35875 | 0.100 |
Why?
| | Sialorrhea | 1 | 2013 | 2 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1318 | 0.100 |
Why?
| | Interferon-gamma | 4 | 2010 | 784 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3409 | 0.090 |
Why?
| | Metabolic Diseases | 1 | 2013 | 114 | 0.090 |
Why?
| | Neuromuscular Agents | 1 | 2013 | 45 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 250 | 0.090 |
Why?
| | Botulinum Toxins, Type A | 1 | 2013 | 58 | 0.090 |
Why?
| | Biomarkers | 2 | 2017 | 4271 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6048 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 333 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 1129 | 0.080 |
Why?
| | Macrophages, Alveolar | 2 | 2014 | 368 | 0.080 |
Why?
| | Critical Care | 1 | 1997 | 695 | 0.080 |
Why?
| | Lymphocyte Activation | 3 | 2010 | 1126 | 0.080 |
Why?
| | Prospective Studies | 3 | 2024 | 7990 | 0.080 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 395 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5408 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 3185 | 0.080 |
Why?
| | Patient Admission | 1 | 2012 | 218 | 0.080 |
Why?
| | Animals | 11 | 2014 | 38058 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 178 | 0.080 |
Why?
| | Cause of Death | 1 | 2012 | 471 | 0.080 |
Why?
| | Child, Preschool | 1 | 2024 | 11787 | 0.070 |
Why?
| | Hemorrhage | 1 | 2014 | 809 | 0.070 |
Why?
| | Lymphocyte Subsets | 1 | 2009 | 83 | 0.070 |
Why?
| | Risk Factors | 1 | 2023 | 10779 | 0.070 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 320 | 0.070 |
Why?
| | Prognosis | 1 | 2017 | 4282 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1325 | 0.070 |
Why?
| | Oximetry | 1 | 2009 | 126 | 0.070 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2008 | 51 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1716 | 0.070 |
Why?
| | Aged | 5 | 2025 | 25913 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2875 | 0.070 |
Why?
| | Chronic Disease | 3 | 2010 | 1813 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2009 | 1173 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 320 | 0.070 |
Why?
| | Monocytes | 1 | 2010 | 538 | 0.060 |
Why?
| | Granuloma | 1 | 2007 | 96 | 0.060 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 177 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2009 | 379 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2008 | 364 | 0.060 |
Why?
| | Observer Variation | 2 | 2024 | 355 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 5992 | 0.060 |
Why?
| | Patient Discharge | 1 | 2012 | 983 | 0.060 |
Why?
| | Fibrosis | 2 | 2023 | 548 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2010 | 3121 | 0.060 |
Why?
| | Prevalence | 1 | 2012 | 2834 | 0.050 |
Why?
| | Adolescent | 1 | 2024 | 22428 | 0.050 |
Why?
| | Dendritic Cells | 1 | 2008 | 499 | 0.050 |
Why?
| | Pneumonia | 1 | 2010 | 631 | 0.050 |
Why?
| | Asymptomatic Diseases | 1 | 2024 | 102 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2008 | 4154 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1985 | 0.050 |
Why?
| | Lung Diseases, Interstitial | 1 | 2009 | 660 | 0.050 |
Why?
| | Cardiac Volume | 1 | 2001 | 15 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 917 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2013 | 11679 | 0.040 |
Why?
| | Phenotype | 1 | 2008 | 3162 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 457 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2025 | 3604 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 1045 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1782 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 289 | 0.030 |
Why?
| | Hemosiderin | 1 | 2014 | 2 | 0.030 |
Why?
| | Bleeding Time | 1 | 2014 | 7 | 0.030 |
Why?
| | Time Factors | 1 | 2025 | 7173 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 397 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2013 | 88 | 0.030 |
Why?
| | Fibrin | 1 | 2014 | 91 | 0.020 |
Why?
| | Myofibroblasts | 1 | 2014 | 143 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1997 | 1489 | 0.020 |
Why?
| | Movement Disorders | 1 | 2013 | 69 | 0.020 |
Why?
| | Injections | 1 | 2013 | 196 | 0.020 |
Why?
| | Intubation, Gastrointestinal | 1 | 2013 | 82 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 779 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2013 | 160 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2014 | 4557 | 0.020 |
Why?
| | Patient Care Team | 1 | 1997 | 689 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 36 | 0.020 |
Why?
| | Infrared Rays | 1 | 2009 | 27 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 206 | 0.020 |
Why?
| | Cell Polarity | 1 | 2010 | 137 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 299 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 2089 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 704 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 249 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 327 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 205 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2527 | 0.020 |
Why?
| | Aerosols | 1 | 2008 | 186 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 574 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2112 | 0.020 |
Why?
| | Rats | 1 | 2013 | 5597 | 0.010 |
Why?
| | Oxygen | 1 | 2009 | 995 | 0.010 |
Why?
| | Hospitalization | 1 | 2013 | 2433 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5960 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 158 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1982 | 0.010 |
Why?
| | Swine | 1 | 2001 | 833 | 0.010 |
Why?
|
|
Higgins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|